[1] Smith R, Russell RG, Bishop M. Diphosphonates and Page's disease of bone[J]. Lancet, 1971, 1(7706):945-947.
[2] van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)[J]. Lancet, 1979, 1(8120):803-805.
[3] Eastell R, Walsh JS, Watts NB, et al. Bisphosphonates for postmenopausal osteoporosis[J]. Bone, 2011, 49(1):82-88.
[4] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117. [5] Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice[J]. Mayo Clin Proc, 2008, 83(9):1032-1045.
[6] Panzavolta S, Torricelli P, Bracci B, et al. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells[J]. J Inorg Biochem, 2009, 103(1):101-106.
[7] Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[J]. J Bone Miner Res, 2007, 22(10):1479-1491.
[8] Stresing V, Fournier PG, Bellahcene A, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase [J]. Bone, 2011, 48(2):259-266.
[9] Coxon FP, Thompson K, Roelofs AJ, et al. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells[J]. Bone, 2008, 42(5):848-860.
[10] Kikuiri T, Kim I, Yamaza T, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice[J]. J Bone Miner Res, 2010, 25(7):1668-1679.
[11] Burr DB, Allen MR. Mandibular necrosis in beagle dogs treated with bisphosphonates[J]. Orthod Craniofac Res, 2009, 12(3):221-228.
[12] Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs[J]. J Bone Miner Res, 2010, 25(1):98-105.
[13] Li Y, Xu J, Mao L, et al. Allogeneic mesenchymal stem cell therapy for bisphosphonate-related jaw osteonecrosis in Swine[J]. Stem Cells Dev, 2013, 22(14):2047-2056.
[14] Sonis ST, Watkins BA, Lyng GD, et al. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients[J]. Oral Oncol, 2009, 45(2):164-172.
[15] Bi Y, Gao Y, Ehirchiou D, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice[J]. Am J Pathol, 2010, 177(1):280-290.
[16] Barba-Recreo P, de Vera JL DCP, Garcia-Arranz M, et al. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats[J]. J Craniomaxillofac Surg, 2014, 42(6):744-750.
[17] 马泽云, 王衣祥. 建立大鼠双膦酸盐相关颌骨骨坏死模型并初步分析其发病原因[J]. 北京大学学报(医学版), 2014, (06):945-949.
[18] Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition[J]. J Oral Maxillofac Surg, 2009, 67(12):2698-2699.
[19] Lesclous P, Abi NS, Carrel JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation[J]. Bone, 2009, 45(5):843-852. |